NEW YORK (GenomeWeb News) – Predictive biology company BioSeek said today that it will collaborate with Ono Pharmaceutical in a drug target screening collaboration.
Under a three-year agreement, BioSeek will use its BioMap platform in a collaboration that will focus on a specific drug target class designated by Ono.
BioSeek will use the Biomap to perform phenotypic screening and hit identification, lead optimization, and clinical candidate selection. For its efforts, BioSeek, which is a subsidiary of Asterand, will receive research funding and a milestone payment linked to development of the Ono drug candidate.
Osaka, Japan-based Ono will have the worldwide rights to develop and sell any pharmaceutical products discovered through the collaboration.
The BioMap systems use cell-based models of pathway interactions to understand toxicological properties of compounds including target effects, dose responses, and the discrimination of related compounds.